Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References FTP Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:cyclobutanes
go back to main search page
Accession:CHEBI:156473 term browser browse the term
Definition:Cyclobutane and its derivatives formed by substitution.
Synonyms:xref_mesh: MESH:D003503

show annotations for term's descendants           Sort by:
 
cyclobutanes term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO Cyclobutanes results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277 		JBrowse link
carboplatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A decreases expression ISO Carboplatin results in decreased expression of ABCB1 mRNA; Carboplatin results in decreased expression of ABCB1 protein CTD PMID:27692344 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases expression EXP Carboplatin results in decreased expression of ABCB4 mRNA CTD PMID:18172885 NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression ISO Carboplatin results in decreased expression of ABCC1 mRNA; Carboplatin results in decreased expression of ABCC1 protein CTD PMID:27692344 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression ISO Carboplatin results in decreased expression of ABCC2 mRNA; Carboplatin results in decreased expression of ABCC2 protein CTD PMID:27692344 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 decreases expression ISO Carboplatin results in decreased expression of ABCG2 mRNA; Carboplatin results in decreased expression of ABCG2 protein CTD PMID:27692344 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621 		JBrowse link
G Acvr1c activin A receptor type 1C increases response to substance ISO ACVR1C results in increased susceptibility to Carboplatin CTD PMID:21224400 NCBI chr 3:44,272,859...44,342,501
Ensembl chr 3:44,270,653...44,342,355 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B increases expression EXP Carboplatin results in increased expression of AKR1B1 mRNA CTD PMID:18172885 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein] CTD PMID:18483861 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258 		JBrowse link
G Alas2 5'-aminolevulinate synthase 2 decreases expression EXP Carboplatin results in decreased expression of ALAS2 mRNA CTD PMID:21296123 NCBI chr  X:23,167,576...23,187,356
Ensembl chr  X:23,167,696...23,187,341 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 affects response to substance ISO ALDH1A1 protein affects the susceptibility to Carboplatin CTD PMID:18854779 NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330 		JBrowse link
G Aldh3a1 aldehyde dehydrogenase 3 family, member A1 affects response to substance ISO ALDH3A1 protein affects the susceptibility to Carboplatin CTD PMID:18854779 NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876 		JBrowse link
G Anxa4 annexin A4 decreases response to substance
affects localization
multiple interactions		 ISO ANXA4 protein results in decreased susceptibility to Carboplatin
Carboplatin affects the localization of ANXA4 protein
ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin]		 CTD PMID:24150977 NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580 		JBrowse link
G Arfgef1 ADP ribosylation factor guanine nucleotide exchange factor 1 increases response to substance ISO ARFGEF1 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr 5:8,666,046...8,760,458
Ensembl chr 5:8,666,200...8,760,458 		JBrowse link
G Atp1a1 ATPase Na+/K+ transporting subunit alpha 1 decreases expression EXP Carboplatin results in decreased expression of ATP1A1 mRNA CTD PMID:18172885 NCBI chr 2:204,003,742...204,032,023
Ensembl chr 2:204,003,742...204,032,023 		JBrowse link
G Atp7a ATPase copper transporting alpha affects localization
multiple interactions		 ISO Carboplatin affects the localization of ATP7A protein
[MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Carboplatin; ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin]		 CTD PMID:24038379 PMID:24150977 NCBI chr  X:77,076,085...77,193,644
Ensembl chr  X:77,076,106...77,193,644 		JBrowse link
G Atp7b ATPase copper transporting beta multiple interactions ISO ATP7B protein binds to and results in increased metabolism of Carboplatin CTD PMID:23751120 NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression
multiple interactions		 ISO Carboplatin results in decreased expression of BAX mRNA
Carboplatin results in increased cleavage of and results in increased expression of BAX protein		 CTD PMID:15131059 PMID:15576332 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO Carboplatin results in decreased expression of BCL2 mRNA; Carboplatin results in decreased expression of BCL2 protein CTD PMID:9664115 PMID:15576332 PMID:15996812 PMID:17404015 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374 		JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression
multiple interactions		 ISO
EXP		 Carboplatin results in decreased expression of BCL2L1 protein
Acetylcysteine inhibits the reaction [Carboplatin results in decreased expression of BCL2L1 protein]		 CTD PMID:18483861 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810 		JBrowse link
G Bcl2l12 BCL2 like 12 increases expression ISO Carboplatin results in increased expression of BCL2L12 mRNA CTD PMID:15576332 NCBI chr 1:100,984,550...100,993,269
Ensembl chr 1:100,984,550...100,993,269 		JBrowse link
G Becn1 beclin 1 decreases expression
multiple interactions		 ISO Carboplatin results in decreased expression of BECN1 protein
Carboplatin promotes the reaction [Chloroquine results in decreased expression of BECN1 protein]; Chloroquine promotes the reaction [Carboplatin results in decreased expression of BECN1 protein]		 CTD PMID:27692344 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases response to substance ISO BIRC2 protein results in decreased susceptibility to Carboplatin CTD PMID:10815900 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142 		JBrowse link
G Blmh bleomycin hydrolase decreases expression EXP Carboplatin results in decreased expression of BLMH mRNA CTD PMID:18172885 NCBI chr10:63,197,367...63,240,447
Ensembl chr10:63,197,364...63,240,332 		JBrowse link
G Brca1 BRCA1, DNA repair associated decreases activity ISO Carboplatin results in decreased activity of BRCA1 protein CTD PMID:20878461 NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681 		JBrowse link
G Camkk2 calcium/calmodulin-dependent protein kinase kinase 2 affects response to substance ISO CAMKK2 protein affects the susceptibility to Carboplatin CTD PMID:28634229 NCBI chr12:39,253,409...39,302,601
Ensembl chr12:39,253,409...39,302,601 		JBrowse link
G Canx calnexin decreases expression EXP Carboplatin results in decreased expression of CANX mRNA CTD PMID:18172885 NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861 		JBrowse link
G Casp2 caspase 2 decreases expression EXP Carboplatin results in decreased expression of CASP2 mRNA CTD PMID:18172885 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases expression		 ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein]; Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein]
Carboplatin results in increased expression of CASP3 protein
Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]
Carboplatin results in increased expression of CASP3 mRNA		 CTD PMID:15576332 PMID:16275998 PMID:18483861 PMID:20368269 PMID:22302033 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204 		JBrowse link
G Casp7 caspase 7 increases activity
multiple interactions		 ISO Carboplatin results in increased activity of CASP7 protein
palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]		 CTD PMID:22302033 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774 		JBrowse link
G Casp9 caspase 9 increases activity
decreases expression
multiple interactions
increases expression		 ISO
EXP		 Carboplatin results in increased activity of CASP9 protein
Carboplatin results in decreased expression of CASP9 mRNA
Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]		 CTD PMID:15576332 PMID:15996812 PMID:17404015 PMID:18483861 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778 		JBrowse link
G Cat catalase decreases activity
decreases expression
multiple interactions		 EXP Carboplatin results in decreased activity of CAT protein
Carboplatin results in decreased expression of CAT protein
Carboplatin results in decreased expression of and results in decreased activity of CAT protein		 CTD PMID:11124453 PMID:15109710 PMID:15225673 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058 		JBrowse link
G Cd274 CD274 molecule decreases expression ISO Carboplatin results in decreased expression of CD274; Carboplatin results in decreased expression of CD274 protein CTD PMID:21765211 PMID:27692344 NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943 		JBrowse link
G Cd44 CD44 molecule (Indian blood group) decreases expression EXP Carboplatin results in decreased expression of CD44 mRNA CTD PMID:18172885 NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658 		JBrowse link
G Cdc25b cell division cycle 25B decreases expression EXP Carboplatin results in decreased expression of CDC25B mRNA CTD PMID:21296123 NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339 		JBrowse link
G Cdc42 cell division cycle 42 decreases expression EXP Carboplatin results in decreased expression of CDC42 mRNA CTD PMID:18172885 NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO
EXP		 Carboplatin results in increased expression of CDKN1A protein
Carboplatin results in increased expression of CDKN1A mRNA		 CTD PMID:9664115 PMID:18172885 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 increases expression EXP Carboplatin results in increased expression of CITED2 mRNA CTD PMID:18172885 NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786 		JBrowse link
G Clu clusterin decreases expression EXP Carboplatin results in decreased expression of CLU mRNA CTD PMID:18172885 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857 		JBrowse link
G Cops5 COP9 signalosome subunit 5 increases response to substance ISO COPS5 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr 5:8,876,090...8,894,345
Ensembl chr 5:8,876,044...8,894,339 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions EXP Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CYCS protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein] CTD PMID:18483861 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326 		JBrowse link
G Dct dopachrome tautomerase decreases response to substance ISO DCT protein results in decreased susceptibility to Carboplatin CTD PMID:15897911 NCBI chr15:103,208,174...103,245,033
Ensembl chr15:103,208,258...103,244,494 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression EXP Carboplatin results in increased expression of DDIT3 mRNA CTD PMID:18172885 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084 		JBrowse link
G Dpyd dihydropyrimidine dehydrogenase multiple interactions ISO PCNA mRNA affects the reaction [DPYD mRNA affects the susceptibility to Carboplatin] CTD PMID:16685392 NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha affects phosphorylation ISO Carboplatin affects the phosphorylation of EIF2S1 protein CTD PMID:29053414 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041 		JBrowse link
G Epcam epithelial cell adhesion molecule multiple interactions ISO [Paclitaxel co-treated with Carboplatin] results in increased expression of EPCAM protein CTD PMID:12695858 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216 		JBrowse link
G Epo erythropoietin increases expression EXP Carboplatin results in increased expression of EPO protein CTD PMID:17891399 NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] CTD PMID:16446318 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728 		JBrowse link
G Fas Fas cell surface death receptor increases expression ISO Carboplatin results in increased expression of FAS mRNA CTD PMID:15576332 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790 		JBrowse link
G Fshb follicle stimulating hormone subunit beta increases expression EXP Carboplatin results in increased expression of FSHB protein CTD PMID:8776818 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131 		JBrowse link
G Gsr glutathione-disulfide reductase decreases activity EXP Carboplatin results in decreased activity of GSR protein CTD PMID:11124453 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 affects response to substance ISO GSTP1 gene affects the susceptibility to Carboplatin CTD PMID:12360105 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147 		JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions		 ISO Carboplatin results in increased expression of H2AX protein
palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]		 CTD PMID:22302033 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981 		JBrowse link
G Hax1 HCLS1 associated protein X-1 multiple interactions EXP Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein] CTD PMID:18483861 NCBI chr 2:189,330,900...189,333,305
Ensembl chr 2:189,330,902...189,333,322 		JBrowse link
G Hbb hemoglobin subunit beta decreases expression EXP Carboplatin results in decreased expression of HBB mRNA CTD PMID:21296123 NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
decreases response to substance
decreases expression		 ISO
EXP		 HMOX1 protein inhibits the reaction [Carboplatin results in increased activity of NFATC4]
Carboplatin results in increased expression of HMOX1 mRNA
HMOX1 protein results in decreased susceptibility to Carboplatin
Carboplatin results in decreased expression of HMOX1 mRNA		 CTD PMID:18172885 PMID:20368269 PMID:21198546 PMID:26260164 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456 		JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 decreases expression EXP Carboplatin results in decreased expression of HSD17B4 mRNA CTD PMID:18172885 NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A increases expression EXP Carboplatin results in increased expression of HSPA1A mRNA CTD PMID:18172885 NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases expression EXP Carboplatin results in increased expression of HSPA1B mRNA CTD PMID:18172885 NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 decreases expression EXP Carboplatin results in decreased expression of HSPA5 mRNA CTD PMID:18172885 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression EXP Carboplatin results in increased expression of HSPB1 mRNA CTD PMID:18172885 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049 		JBrowse link
G Igf2r insulin-like growth factor 2 receptor decreases expression EXP Carboplatin results in decreased expression of IGF2R mRNA CTD PMID:18172885 NCBI chr 1:48,176,095...48,264,482
Ensembl chr 1:48,176,106...48,264,477 		JBrowse link
G Il6 interleukin 6 decreases response to substance ISO IL6 protein results in decreased susceptibility to Carboplatin CTD PMID:7834629 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807 		JBrowse link
G Il6r interleukin 6 receptor decreases response to substance ISO IL6R protein results in decreased susceptibility to Carboplatin CTD PMID:7834629 NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression EXP Carboplatin results in decreased expression of JUN mRNA CTD PMID:18172885 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277 		JBrowse link
G Map3k1 mitogen-activated protein kinase kinase kinase 1 decreases expression EXP Carboplatin results in decreased expression of MAP3K1 mRNA CTD PMID:18172885 NCBI chr 2:43,329,516...43,393,203
Ensembl chr 2:43,329,516...43,393,207 		JBrowse link
G Map3k12 mitogen activated protein kinase kinase kinase 12 decreases expression EXP Carboplatin results in decreased expression of MAP3K12 mRNA CTD PMID:18172885 NCBI chr 7:144,102,275...144,120,306
Ensembl chr 7:144,102,680...144,109,116 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases expression EXP Carboplatin results in decreased expression of MAPK14 mRNA CTD PMID:18172885 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137 		JBrowse link
G Mapk6 mitogen-activated protein kinase 6 decreases expression EXP Carboplatin results in decreased expression of MAPK6 mRNA CTD PMID:18172885 NCBI chr 8:82,328,013...82,351,108
Ensembl chr 8:82,328,020...82,351,108 		JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase decreases expression EXP Carboplatin results in decreased expression of MGMT mRNA CTD PMID:18172885 NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190 		JBrowse link
G Mir155 microRNA 155 multiple interactions ISO [Carboplatin co-treated with Chloroquine] results in increased expression of MIR155 mRNA CTD PMID:27692344 NCBI chr11:24,176,603...24,176,667
Ensembl chr11:24,176,603...24,176,667 		JBrowse link
G Mpo myeloperoxidase multiple interactions EXP [Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein CTD PMID:18852009 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260 		JBrowse link
G Msh2 mutS homolog 2 decreases expression EXP Carboplatin results in decreased expression of MSH2 mRNA CTD PMID:18172885 NCBI chr 6:11,215,951...11,274,916
Ensembl chr 6:11,215,963...11,274,932 		JBrowse link
G Mt1 metallothionein 1 decreases expression EXP Carboplatin results in decreased expression of MT1A mRNA CTD PMID:18172885 NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases response to substance ISO MYC protein results in increased susceptibility to Carboplatin CTD PMID:21324178 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240 		JBrowse link
G Nanog Nanog homeobox increases expression ISO Carboplatin results in increased expression of NANOG mRNA CTD PMID:25605917 NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268 		JBrowse link
G Nbas NBAS subunit of NRZ tethering complex affects response to substance ISO NBAS intron polymorphism affects the susceptibility to Carboplatin CTD PMID:21844884 NCBI chr 6:38,474,773...38,777,146
Ensembl chr 6:38,474,804...38,777,806 		JBrowse link
G Nckap1 NCK-associated protein 1 decreases expression EXP Carboplatin results in decreased expression of NCKAP1 mRNA CTD PMID:18172885 NCBI chr 3:67,725,180...67,804,680
Ensembl chr 3:67,725,947...67,787,990 		JBrowse link
G Nfatc4 nuclear factor of activated T-cells 4 multiple interactions
increases activity		 ISO
EXP		 HMOX1 protein inhibits the reaction [Carboplatin results in increased activity of NFATC4] CTD PMID:21198546 NCBI chr15:34,493,163...34,502,238
Ensembl chr15:34,493,138...34,504,326 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
decreases expression		 ISO
EXP		 Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]
Carboplatin results in decreased expression of NFKB1 mRNA		 CTD PMID:12675310 PMID:18172885 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689 		JBrowse link
G Nfkbia NFKB inhibitor alpha decreases phosphorylation
multiple interactions		 ISO Carboplatin results in decreased phosphorylation of NFKBIA protein
NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]		 CTD PMID:12675310 PMID:15120608 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457 		JBrowse link
G Nodal nodal growth differentiation factor increases response to substance ISO NODAL results in increased susceptibility to Carboplatin CTD PMID:21224400 NCBI chr20:31,035,729...31,044,096
Ensembl chr20:31,035,729...31,044,096 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression EXP Carboplatin results in increased expression of NQO1 mRNA CTD PMID:18172885 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180 		JBrowse link
G Nras NRAS proto-oncogene, GTPase decreases expression EXP Carboplatin results in decreased expression of NRAS mRNA CTD PMID:18172885 NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791 		JBrowse link
G Olr325 olfactory receptor 325 affects response to substance ISO OR4D6 gene SNP affects the susceptibility to Carboplatin CTD PMID:26378035 NCBI chr 1:228,545,913...228,546,857
Ensembl chr 1:228,545,913...228,546,857 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage ISO Carboplatin results in increased cleavage of PARP1 protein CTD PMID:15996812 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716 		JBrowse link
G Pawr pro-apoptotic WT1 regulator decreases expression EXP Carboplatin results in decreased expression of PAWR mRNA CTD PMID:18172885 NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
increases expression		 ISO
EXP		 PCNA mRNA affects the reaction [DPYD mRNA affects the susceptibility to Carboplatin]; PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin]
Carboplatin results in increased expression of PCNA mRNA		 CTD PMID:16685392 PMID:18172885 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570 		JBrowse link
G Pdcd1lg2 programmed cell death 1 ligand 2 decreases expression
multiple interactions		 ISO Carboplatin results in decreased expression of PDCD1LG2
STAT6 gene mutant form inhibits the reaction [Carboplatin results in decreased expression of PDCD1LG2]		 CTD PMID:21765211 NCBI chr 1:247,562,202...247,629,279
Ensembl chr 1:247,562,202...247,627,193 		JBrowse link
G Pdia4 protein disulfide isomerase family A, member 4 decreases expression EXP Carboplatin results in decreased expression of PDIA4 mRNA CTD PMID:18172885 NCBI chr 4:77,470,636...77,489,535
Ensembl chr 4:77,470,636...77,489,535 		JBrowse link
G Pdia6 protein disulfide isomerase family A, member 6 decreases expression EXP Carboplatin results in decreased expression of PDIA6 mRNA CTD PMID:18172885 NCBI chr 6:42,568,269...42,585,654
Ensembl chr 6:42,568,220...42,585,652 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases expression ISO Carboplatin results in increased expression of PMAIP1 protein CTD PMID:20802529 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102 		JBrowse link
G Psmb2 proteasome 20S subunit beta 2 increases expression EXP Carboplatin results in increased expression of PSMB2 mRNA CTD PMID:18172885 NCBI chr 5:144,702,004...144,734,220
Ensembl chr 5:144,701,949...144,734,257 		JBrowse link
G Psmb4 proteasome 20S subunit beta 4 decreases expression EXP Carboplatin results in decreased expression of PSMB4 mRNA CTD PMID:18172885 NCBI chr 2:196,043,546...196,046,320
Ensembl chr 2:196,043,618...196,046,311 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases response to substance
multiple interactions		 ISO PTGS2 protein results in decreased susceptibility to Carboplatin
wortmannin inhibits the reaction [PTGS2 protein results in decreased susceptibility to Carboplatin]		 CTD PMID:18089846 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335 		JBrowse link
G Rab10 RAB10, member RAS oncogene family decreases expression EXP Carboplatin results in decreased expression of RAB10 mRNA CTD PMID:18172885 NCBI chr 6:27,668,387...27,721,120
Ensembl chr 6:27,668,403...27,721,120 		JBrowse link
G Rbm17 RNA binding motif protein 17 decreases response to substance ISO RBM17 protein results in decreased susceptibility to Carboplatin CTD PMID:16061639 NCBI chr17:70,586,345...70,603,289
Ensembl chr17:70,586,394...70,603,267 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Carboplatin results in decreased localization of and results in decreased activity of RELA protein; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:12675310 PMID:15120608 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249 		JBrowse link
G Scd2 stearoyl-Coenzyme A desaturase 2 decreases expression EXP Carboplatin results in decreased expression of SCD2 mRNA CTD PMID:18172885 NCBI chr 1:264,059,374...264,072,433
Ensembl chr 1:264,059,374...264,072,433 		JBrowse link
G Sik1 salt-inducible kinase 1 increases response to substance ISO SIK1 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr20:10,670,747...10,680,279
Ensembl chr20:10,668,411...10,680,283 		JBrowse link
G Slc31a1 solute carrier family 31 member 1 decreases response to substance
multiple interactions
increases import
increases uptake
increases response to substance		 ISO
EXP		 SLC31A1 gene mutant form results in decreased susceptibility to Carboplatin
[Penicillamine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [Trientine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin
SLC31A1 protein results in increased import of Carboplatin
SLC31A1 protein results in increased uptake of Carboplatin
SLC31A1 protein results in increased susceptibility to Carboplatin		 CTD PMID:15634647 PMID:16847145 PMID:19509135 PMID:22914438 PMID:23123662 NCBI chr 5:78,222,504...78,249,358
Ensembl chr 5:78,222,504...78,249,358 		JBrowse link
G Slc31a2 solute carrier family 31 member 2 decreases uptake ISO SLC31A2 protein results in decreased uptake of Carboplatin CTD PMID:19509135 NCBI chr 5:78,120,606...78,131,111
Ensembl chr 5:78,120,607...78,131,114 		JBrowse link
G Smo smoothened, frizzled class receptor increases expression ISO Carboplatin results in increased expression of SMO mRNA CTD PMID:25605917 NCBI chr 4:57,019,941...57,041,779
Ensembl chr 4:57,019,941...57,042,770 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
decreases expression		 EXP Carboplatin results in decreased expression of and results in decreased activity of SOD1 protein
Carboplatin results in decreased expression of SOD1 protein		 CTD PMID:15109710 PMID:15225673 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
decreases expression		 EXP Carboplatin results in increased expression of and results in increased activity of SOD2 protein
Carboplatin results in decreased expression of SOD2 protein		 CTD PMID:15109710 PMID:15225673 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587 		JBrowse link
G Sox2 SRY-box transcription factor 2 increases expression ISO Carboplatin results in increased expression of SOX2 mRNA CTD PMID:25605917 NCBI chr 2:121,165,137...121,167,545
Ensembl chr 2:121,165,137...121,167,545 		JBrowse link
G Stat6 signal transducer and activator of transcription 6 multiple interactions ISO STAT6 gene mutant form inhibits the reaction [Carboplatin results in decreased expression of PDCD1LG2] CTD PMID:21765211 NCBI chr 7:70,946,228...70,963,542
Ensembl chr 7:70,946,228...70,964,484 		JBrowse link
G Stk39 serine threonine kinase 39 decreases expression EXP Carboplatin results in decreased expression of STK39 mRNA CTD PMID:18172885 NCBI chr 3:54,359,449...54,625,702
Ensembl chr 3:54,359,451...54,625,414 		JBrowse link
G Stx2 syntaxin 2 increases response to substance ISO STX2 protein results in increased susceptibility to Carboplatin CTD PMID:24039787 NCBI chr12:31,324,203...31,360,249
Ensembl chr12:31,335,372...31,360,254 		JBrowse link
G Tfap2a transcription factor AP-2 alpha increases response to substance ISO TFAP2A protein results in increased susceptibility to Carboplatin CTD PMID:16204029 NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457 		JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein CTD PMID:18852009 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 		JBrowse link
G Top2a DNA topoisomerase II alpha multiple interactions ISO TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide] CTD PMID:11325482 NCBI chr10:86,901,467...86,930,947
Ensembl chr10:86,901,007...86,932,154 		JBrowse link
G Tp53 tumor protein p53 increases expression ISO Carboplatin results in increased expression of TP53 protein CTD PMID:9664115 PMID:15131059 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449 		JBrowse link
G Tyms thymidylate synthetase multiple interactions ISO PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin] CTD PMID:16685392 NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564 		JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 decreases expression EXP Carboplatin results in decreased expression of UGT1A6 mRNA CTD PMID:18172885 NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822 		JBrowse link
G Vim vimentin decreases expression EXP Carboplatin results in decreased expression of VIM mRNA CTD PMID:18172885 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212 		JBrowse link
G Xdh xanthine dehydrogenase affects activity EXP Carboplatin affects the activity of XDH protein CTD PMID:15225673 NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494 		JBrowse link
G Xpc XPC complex subunit, DNA damage recognition and repair factor decreases response to substance ISO XPC results in decreased susceptibility to Carboplatin CTD PMID:19372135 NCBI chr 4:123,134,457...123,161,985
Ensembl chr 4:123,134,457...123,161,985 		JBrowse link
G Zfp36l1 zinc finger protein 36, C3H type-like 1 decreases expression EXP Carboplatin results in decreased expression of ZFP36L1 mRNA CTD PMID:18172885 NCBI chr 6:103,308,032...103,313,074
Ensembl chr 6:103,308,045...103,313,074 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19840
    chemical entity 19840
      group 19755
        polyatomic entity 19754
          molecule 19586
            cyclic compound 19402
              organic cyclic compound 19364
                carbocyclic compound 18278
                  cyclobutanes 119
                    1-AMINOCYCLOBUTANECARBOXLIC ACID 0
                    3-ETHYLAMINO-4-METHYLAMINO-CYCLOBUTANE-1,2-DIONE 0
                    3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol 0
                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                    N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6R,9R)-8-(cyclobutanecarbonyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                    N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    Pipercyclobutanamide A(rel) 0
                    cis-1,2-Diphenylcyclobutane 0
                    cyclobutane + 0
                    cyclobutanecarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester 0
                    cyclobutanedicarboxylate + 118
                    cyclobutanedicarboxylic acid + 0
                    cyclobutrifluram 0
                    octafluorocyclobutane 0
                    trans-1,2-Diphenylcyclobutane 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19840
    subatomic particle 19838
      composite particle 19838
        hadron 19838
          baryon 19838
            nucleon 19838
              atomic nucleus 19838
                atom 19838
                  main group element atom 19730
                    p-block element atom 19730
                      p-block molecular entity 19730
                        carbon group molecular entity 19635
                          organic molecular entity 19624
                            organic molecule 19555
                              organic cyclic compound 19364
                                carbocyclic compound 18278
                                  cyclobutanes 119
                                    1-AMINOCYCLOBUTANECARBOXLIC ACID 0
                                    3-ETHYLAMINO-4-METHYLAMINO-CYCLOBUTANE-1,2-DIONE 0
                                    3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol 0
                                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6R,9R)-8-(cyclobutanecarbonyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                                    N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                    Pipercyclobutanamide A(rel) 0
                                    cis-1,2-Diphenylcyclobutane 0
                                    cyclobutane + 0
                                    cyclobutanecarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester 0
                                    cyclobutanedicarboxylate + 118
                                    cyclobutanedicarboxylic acid + 0
                                    cyclobutrifluram 0
                                    octafluorocyclobutane 0
                                    trans-1,2-Diphenylcyclobutane 0
paths to the root